ProfileGDS5678 / 1419729_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 51% 50% 50% 49% 52% 54% 50% 49% 50% 51% 51% 52% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2768451
GSM967853U87-EV human glioblastoma xenograft - Control 23.2111851
GSM967854U87-EV human glioblastoma xenograft - Control 33.2126950
GSM967855U87-EV human glioblastoma xenograft - Control 43.1373250
GSM967856U87-EV human glioblastoma xenograft - Control 53.1319349
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3629152
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.438454
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2064950
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1546549
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1939250
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2293351
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1817851
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.280652
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2047150